Idiopathic nephrotic syndrome represents the most common type of primary glomerular disease in children: glucocorticoids (GCs) are the first-line therapy, even if considerable interindividual differences in thepir efficacy and side effects have been reported. Immunosuppressive and anti-inflammatory effects of these drugs are mainly due to the GC-mediated transcription regulation of pro- and anti-inflammatory genes. This mechanism of action is the result of a complex multistep pathway that involves the glucocorticoid receptor and several other proteins, encoded by polymorphic genes. Aim of this review is to highlight the current knowledge on genetic variants that could affect GC response, particularly focusing on children with idiopathic nephrotic syndrome.

Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome

CUZZONI, EVA;DE IUDICIBUS, SARA;FRANCA, RAFFAELLA;STOCCO, GABRIELE;LUCAFO, MARIANNA;PELIN, MARCO;DECORTI, GIULIANA
2015

Abstract

Idiopathic nephrotic syndrome represents the most common type of primary glomerular disease in children: glucocorticoids (GCs) are the first-line therapy, even if considerable interindividual differences in thepir efficacy and side effects have been reported. Immunosuppressive and anti-inflammatory effects of these drugs are mainly due to the GC-mediated transcription regulation of pro- and anti-inflammatory genes. This mechanism of action is the result of a complex multistep pathway that involves the glucocorticoid receptor and several other proteins, encoded by polymorphic genes. Aim of this review is to highlight the current knowledge on genetic variants that could affect GC response, particularly focusing on children with idiopathic nephrotic syndrome.
http://www.futuremedicine.com/loi/pgs
File in questo prodotto:
File Dimensione Formato  
Cuzzoni et al., Pharmacogenomics 2015.pdf

non disponibili

Descrizione: pdf versione editoriale-ahead of print
Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 2.02 MB
Formato Adobe PDF
2.02 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Review SNI pharmacogenomics.pdf

accesso aperto

Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Creative commons
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/2847554
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
social impact